vs
Ginkgo Bioworks Holdings, Inc.（DNA）与FVCBankcorp, Inc.（FVCB）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是FVCBankcorp, Inc.的2.0倍（$33.4M vs $16.9M），FVCBankcorp, Inc.同比增速更快（4377.5% vs -23.8%），FVCBankcorp, Inc.自由现金流更多（$23.8M vs $-47.7M），过去两年FVCBankcorp, Inc.的营收复合增速更高（586.6% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
FVCBankcorp是总部位于美国弗吉尼亚州的银行控股公司，旗下运营社区银行FVCbank，面向大西洋中部地区的中小企业、专业人士及个人客户提供存款、贷款、按揭、财富管理等各类个人及商业银行金融服务。
DNA vs FVCB — 直观对比
营收规模更大
DNA
是对方的2.0倍
$16.9M
营收增速更快
FVCB
高出4401.3%
-23.8%
自由现金流更多
FVCB
多$71.5M
$-47.7M
两年增速更快
FVCB
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $16.9M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 43.7% |
| 净利率 | — | — |
| 营收同比 | -23.8% | 4377.5% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-1.41 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAFVCB
| Q4 25 | $33.4M | $16.9M | ||
| Q3 25 | $38.8M | $416.0K | ||
| Q2 25 | $49.6M | $15.8M | ||
| Q1 25 | $48.3M | $382.0K | ||
| Q4 24 | $43.8M | $378.0K | ||
| Q3 24 | $89.0M | $412.0K | ||
| Q2 24 | $56.2M | $415.0K | ||
| Q1 24 | $37.9M | $359.0K |
净利润DNAFVCB
| Q4 25 | — | — | ||
| Q3 25 | $-80.8M | $5.6M | ||
| Q2 25 | $-60.3M | $5.7M | ||
| Q1 25 | $-91.0M | $5.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-56.4M | $4.7M | ||
| Q2 24 | $-217.2M | $4.2M | ||
| Q1 24 | $-165.9M | $1.3M |
营业利润率DNAFVCB
| Q4 25 | -211.9% | 43.7% | ||
| Q3 25 | -231.8% | — | ||
| Q2 25 | -132.1% | 45.9% | ||
| Q1 25 | -184.1% | — | ||
| Q4 24 | -236.3% | — | ||
| Q3 24 | -62.0% | — | ||
| Q2 24 | -396.7% | — | ||
| Q1 24 | -469.1% | — |
净利率DNAFVCB
| Q4 25 | — | — | ||
| Q3 25 | -207.9% | 1341.1% | ||
| Q2 25 | -121.6% | 36.0% | ||
| Q1 25 | -188.2% | 1352.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -63.3% | 1133.3% | ||
| Q2 24 | -386.4% | 1001.2% | ||
| Q1 24 | -437.3% | 373.3% |
每股收益（稀释后）DNAFVCB
| Q4 25 | $-1.41 | $0.31 | ||
| Q3 25 | $-1.45 | $0.31 | ||
| Q2 25 | $-1.10 | $0.31 | ||
| Q1 25 | $-1.68 | $0.28 | ||
| Q4 24 | $-1.91 | $0.27 | ||
| Q3 24 | $-1.08 | $0.25 | ||
| Q2 24 | $-4.23 | $0.23 | ||
| Q1 24 | $-3.32 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $253.6M |
| 总资产 | $1.1B | $2.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNAFVCB
| Q4 25 | $422.6M | — | ||
| Q3 25 | $495.5M | — | ||
| Q2 25 | $559.4M | — | ||
| Q1 25 | $325.3M | — | ||
| Q4 24 | $561.6M | — | ||
| Q3 24 | $616.2M | — | ||
| Q2 24 | $730.4M | — | ||
| Q1 24 | $840.4M | — |
股东权益DNAFVCB
| Q4 25 | $508.6M | $253.6M | ||
| Q3 25 | $559.8M | $249.8M | ||
| Q2 25 | $613.0M | $243.2M | ||
| Q1 25 | $647.4M | $242.3M | ||
| Q4 24 | $716.1M | $235.4M | ||
| Q3 24 | $797.9M | $230.8M | ||
| Q2 24 | $833.1M | $226.5M | ||
| Q1 24 | $987.3M | $220.7M |
总资产DNAFVCB
| Q4 25 | $1.1B | $2.3B | ||
| Q3 25 | $1.2B | $2.3B | ||
| Q2 25 | $1.2B | $2.2B | ||
| Q1 25 | $1.3B | $2.2B | ||
| Q4 24 | $1.4B | $2.2B | ||
| Q3 24 | $1.5B | $2.3B | ||
| Q2 24 | $1.6B | $2.3B | ||
| Q1 24 | $1.6B | $2.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $23.9M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $23.8M |
| 自由现金流率自由现金流/营收 | -142.8% | 140.7% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $40.0M |
8季度趋势，按日历期对齐
经营现金流DNAFVCB
| Q4 25 | $-47.7M | $23.9M | ||
| Q3 25 | $-31.6M | $7.6M | ||
| Q2 25 | $-40.3M | $3.3M | ||
| Q1 25 | $-51.5M | $5.4M | ||
| Q4 24 | $-42.4M | $18.2M | ||
| Q3 24 | $-103.5M | $4.7M | ||
| Q2 24 | $-84.4M | $1.6M | ||
| Q1 24 | $-89.3M | $7.2M |
自由现金流DNAFVCB
| Q4 25 | $-47.7M | $23.8M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | $-40.3M | $3.3M | ||
| Q1 25 | $-59.1M | $5.4M | ||
| Q4 24 | $-56.1M | $18.1M | ||
| Q3 24 | $-118.6M | $4.6M | ||
| Q2 24 | $-111.4M | $1.5M | ||
| Q1 24 | $-96.0M | $7.1M |
自由现金流率DNAFVCB
| Q4 25 | -142.8% | 140.7% | ||
| Q3 25 | — | 1818.0% | ||
| Q2 25 | -81.2% | 20.8% | ||
| Q1 25 | -122.4% | 1413.6% | ||
| Q4 24 | -128.0% | 4786.0% | ||
| Q3 24 | -133.2% | 1121.8% | ||
| Q2 24 | -198.2% | 361.2% | ||
| Q1 24 | -252.9% | 1988.3% |
资本支出强度DNAFVCB
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.1% | 0.1% | ||
| Q1 25 | 15.8% | 4.2% | ||
| Q4 24 | 31.3% | 37.3% | ||
| Q3 24 | 16.9% | 14.1% | ||
| Q2 24 | 48.1% | 12.8% | ||
| Q1 24 | 17.7% | 3.9% |
现金转化率DNAFVCB
| Q4 25 | — | — | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 0.58× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.00× | ||
| Q2 24 | — | 0.37× | ||
| Q1 24 | — | 5.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
FVCB
暂无分部数据
